Section 174 Relief Is Dead in the Senate: How to Run the Rest of 2024 Without the Fix

What happened

On August 1, 2024, the Senate failed to advance the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024). The motion to invoke cloture — the procedural step needed to move toward a vote — failed by a tally of 48 to 44, well short of the 60 votes required.

The bill had passed the House in late January by an overwhelming bipartisan margin. Its business provisions would have restored the deduction of domestic research and experimental (R&E) costs retroactively for 2022 through 2025, reinstated 100 percent bonus depreciation, and returned the § 163(j) interest limitation to its more favorable EBITDA-based computation. The cloture failure does not formally kill the bill for all time, but it ends any realistic prospect of relief during this filing and planning year.

What this confirms

Earlier in the year, the responsible posture was to file and plan under current law while preserving the ability to capture relief if the bill became law. The Senate vote removes the contingency. Current law is now not just the operative rule but, for practical purposes, the settled rule for the year:

• domestic R&E paid or incurred in tax years beginning after December 31, 2021 must be capitalized and amortized over five years; foreign R&E over fifteen
• the § 163(j) interest limitation continues on its less favorable EBIT basis, with depreciation and amortization no longer added back
• bonus depreciation continues at its phased-down rate, not at a restored 100 percent

These are no longer assumptions held pending legislation. They are the rules to plan against.

Running the rest of the year without the fix

For companies with meaningful research spend, three areas deserve immediate attention now that the upside is gone.

Estimated payments

Any estimated-tax strategy built on the hope of a retroactive deduction needs to be reset. Taxable income for 2024 should be modeled on five-year amortization of domestic R&E. Companies that under-reserved on the assumption of relief may need to true up remaining-quarter payments to avoid an underpayment position at year-end.

The interest limitation

The § 163(j) limitation bites harder without the depreciation and amortization add-back, and the effect compounds for leveraged businesses. The failure of the fix means the tighter computation governs 2024. Modeling the interaction between capitalized R&E, the interest limitation, and overall taxable income matters more for companies that are both research-intensive and leveraged.

Capital spending and bonus depreciation

With 100 percent bonus not restored, placed-in-service timing is a real lever again. Decisions about when to put property in service should reflect the actual phased-down rate, not a hoped-for restoration.

The mistake to avoid

The temptation, even now, is to keep planning as if relief is one vote away. It is not. A failed cloture vote in an election year is a strong signal that the window for this cycle has closed. Continuing to under-reserve or to defer method decisions in anticipation of a fix converts a policy hope into a filing risk.

If Congress revisits § 174 in a future session, the mechanisms to capture the benefit then — amended returns or an accounting-method change — will still exist. Filing correctly under current law does not forfeit future relief. Filing on the assumption of relief that did not arrive does create exposure.

Key takeaways

• The Senate failed to advance H.R. 7024 on August 1, 2024; the cloture vote was 48 to 44, short of the 60 needed.
• The retroactive § 174 fix, 100 percent bonus restoration, and EBITDA-based § 163(j) are off the table for this year.
• Current law governs: five-year amortization of domestic R&E, the tighter § 163(j) computation, and phased-down bonus depreciation.
• Reset estimated payments, model the interest limitation on its current basis, and treat bonus timing as a live decision.

What to do now

1. True up estimated payments to current law.

Reset 2024 income projections to five-year R&E amortization and adjust remaining-quarter payments accordingly.

2. Model § 163(j) on its current footing.

For leveraged, research-heavy companies, the interaction of capitalized R&E and the tighter interest limitation needs a fresh look.

3. Make capital-spending decisions on the real bonus rate.

Plan placed-in-service timing around the phased-down rate, not a restoration that did not happen.

Bottom line

After August 1, the § 174 fix is no longer a live planning variable for this year. The disciplined response is to stop waiting and run the rest of 2024 against the law as it actually is — accurately reserved, correctly computed, and ready to capture relief later only if it genuinely arrives.